2289. Bacterial Causes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Patients with Intravenous Drug Use (IVDU): Phase 3 REVIVE Studies

Risk Factors and Outcomes for Bloodstream Infections (BSI) Among Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)

Acute bacterial skin and skin structure infections (ABSSSI) are a common disease causing patients to seek treatment through the health care system. With the continued increase of drug-resistant bacterial pathogens, these infections are becoming more difficult to successfully cure. Lipoglycopeptides have unique properties that allow the drug to remain active toward both common and challenging pa...

Early endpoints for acute bacterial skin and skin structure infections.

In this issue of the journal, Friedland et al. (4) present a retrospective analysis of the two CANVAS trials (3), employing the newer endpoints from the U.S. Food and Drug Administration (FDA) (7). First, they are to be congratulated for having the foresight to include sufficient measurements in their trial to allow the reanalysis even prior to the issuance of the new guidelines. The analysis e...

Current Use of Intravenous (IV) Long Acting Antibiotic (LAA) Therapy in the Aetna Health Plan among Patients with Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Post-Discharge Antibiotic Therapy in Patients with Acute Bacterial Skin and Skin Structure Infections